JAZZ•benzinga•
Jazz Pharmaceuticals Enters Preliminary $145M Class Settlement Agreement To Resolve Antitrust And Consumer Protection Claims Related To Patent Litigation Settlements For Xyrem, Expected To Record Pre-Tax Charge In Q1 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 8, 2025 by benzinga